^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    serabelisib (MLN1117)

    i
    Associations
    News

    Trials

    Company:
    Eli Lilly, Faeth Therap, Takeda
    Drug class:
    PI3Kα inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations (NCT05300048)
    Phase 1
    Faeth Therapeutics
    Active, not recruiting
    Last update posted :
    02/13/2024
    Initiation :
    04/22/2022
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    PIK3CA • PTEN
    |
    PIK3CA mutation
    |
    albumin-bound paclitaxel • serabelisib (MLN1117)
    TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer (NCT03193853)
    Phase 2
    Joyce O'Shaughnessy
    Completed
    Last update posted :
    08/07/2023
    Initiation :
    07/18/2017
    Primary completion :
    03/17/2020
    Completion :
    12/01/2022
    AR
    |
    AR negative
    |
    cisplatin • albumin-bound paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)
    MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (NCT02724020)
    Phase 2
    Millennium Pharmaceuticals, Inc.
    Completed
    Last update posted :
    11/19/2021
    Initiation :
    06/30/2016
    Primary completion :
    02/03/2020
    Completion :
    10/13/2020
    IL2
    |
    everolimus • sapanisertib (CB-228) • serabelisib (MLN1117)
    A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors (NCT04073680)
    Phase 1b/2
    Petra Pharma
    Unknown status
    Last update posted :
    05/21/2020
    Initiation :
    09/01/2020
    Primary completion :
    07/15/2021
    Completion :
    12/30/2021
    KRAS • PIK3CA
    |
    KRAS mutation • PIK3CA mutation
    |
    serabelisib (MLN1117)
    Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer (NCT01449370)
    Phase 1
    Millennium Pharmaceuticals, Inc.
    Completed
    Last update posted :
    03/09/2017
    Initiation :
    10/01/2011
    Primary completion :
    07/01/2015
    Completion :
    01/01/2016
    PIK3CA
    |
    PIK3CA mutation
    |
    serabelisib (MLN1117)